This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grotta, J. Search for Related Content PubMed PubMed Citation Articles by Grotta, J. Pubmed/NCBI databases Medline Plus Health Information Stroke

(Stroke. 2002;33:306.)
© 2002 American Heart Association, Inc.

Controversies in Stroke

Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs

James Grotta, MD

From the Department of Neurology, University of Texas-Houston Medical School.

Correspondence to Dr. James Grotta, University of Texas-Houston Medical School, 6431 Fannin Street, MSB 7.044, Houston, TX 77030. E-mail james.c.grotta@uth.tmc.edu

Key Words: animal models • clinical trials • neuroprotection • stroke assessment

What we need to carry out in the laboratory and at the bedside are experiments. If our experiments have been positive in the laboratory but negative at the bedside, it is logical to me that at the bedside we need to better emulate the conditions under which the laboratory experiment turns out positive; in other words, we need to do the "rat experiment" in man. Those clinical studies that have adhered to this dictum^1–3 have been the only positive clinical trials to date.

Figure 1 depicts the general design of the rat transient middle cerebral artery occlusion model that is most often used to test neuroprotective drugs. It also depicts the general design of the sort of clinical trial that I postulate must be done to get positive results in stroke patients. There are 4 main areas where clinical trials have departed most from this model. In rats, we take pains to produce lesions of standardized severity in order to better detect a treatment effect; we start by giving the drug soon after the onset of stroke and then determine how much this time to treatment (TTT) can be lengthened; we use models of temporary rather than permanent arterial occlusion; and we increase doses of drug until we see a therapeutic effect.

View larger version (88K): [in this window] [in a new window]   Figure 1. Proposed algorithm for studying neuroprotective drugs in laboratory animals and human stroke patients.

These factors must all be addressed in the design of future clinical trials, and they are listed in Figure 2 along with one . . . [Full Text of this Article]

This article has been cited by other articles:

				R. E. Latchaw, M. J. Alberts, M. H. Lev, J. J. Connors, R. E. Harbaugh, R. T. Higashida, R. Hobson, C. S. Kidwell, W. J. Koroshetz, V. Mathews, et al. Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association Stroke, November 1, 2009; 40(11): 3646 - 3678. [Full Text] [PDF]

				G. Z. Feuerstein and J. Chavez Translational Medicine for Stroke Drug Discovery: The Pharmaceutical Industry Perspective Stroke, March 1, 2009; 40(3_suppl_1): S121 - S125. [Abstract] [Full Text] [PDF]

				M. L. Sacchetti Is It Time to Definitely Abandon Neuroprotection in Acute Ischemic Stroke? Stroke, June 1, 2008; 39(6): 1659 - 1660. [Full Text] [PDF]

				M. S. Hussain and A. Shuaib Research Into Neuroprotection Must Continue ... but With a Different Approach Stroke, February 1, 2008; 39(2): 521 - 522. [Full Text] [PDF]

				J. L. Saver Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials Stroke, November 1, 2007; 38(11): 3055 - 3062. [Abstract] [Full Text] [PDF]

				A. I. Faden and B. Stoica Neuroprotection: Challenges and Opportunities Arch Neurol, June 1, 2007; 64(6): 794 - 800. [Abstract] [Full Text] [PDF]

				M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]

				M. Krams, K. R. Lees, and D. A. Berry The Past Is the Future: Innovative Designs in Acute Stroke Therapy Trials Stroke, June 1, 2005; 36(6): 1341 - 1347. [Full Text] [PDF]

				L. Belayev, V. L. Marcheselli, L. Khoutorova, E. B. Rodriguez de Turco, R. Busto, M. D. Ginsberg, and N. G. Bazan Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection Stroke, January 1, 2005; 36(1): 118 - 123. [Abstract] [Full Text] [PDF]

				C. A. Jungreis, E. Nemoto, F. Boada, and M. B. Horowitz Model of Reversible Cerebral Ischemia in a Monkey Model AJNR Am. J. Neuroradiol., October 1, 2003; 24(9): 1834 - 1836. [Abstract] [Full Text] [PDF]

				L. Zhang, Z. G. Zhang, R. L. Zhang, M. Lu, M. Krams, and M. Chopp Effects of a Selective CD11b/CD18 Antagonist and Recombinant Human Tissue Plasminogen Activator Treatment Alone and in Combination in a Rat Embolic Model of Stroke Stroke, July 1, 2003; 34(7): 1790 - 1795. [Abstract] [Full Text] [PDF]

				M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]

				K.R. Lees, D. Barer, G.A. Ford, W. Hacke, V. Kostulas, A.K. Sharma, and T. Odergren Tolerability of NXY-059 at Higher Target Concentrations in Patients With Acute Stroke Stroke, February 1, 2003; 34(2): 482 - 487. [Abstract] [Full Text] [PDF]

				M. D. Ginsberg Adventures in the Pathophysiology of Brain Ischemia: Penumbra, Gene Expression, Neuroprotection: The 2002 Thomas Willis Lecture Stroke, January 1, 2003; 34(1): 214 - 223. [Abstract] [Full Text] [PDF]

				J. P. Broderick and W. Hacke Treatment of Acute Ischemic Stroke: Part II: Neuroprotection and Medical Management Circulation, September 24, 2002; 106(13): 1736 - 1740. [Full Text] [PDF]